EUCTR2005-000292-17-IT进行中（未招募）不适用
A randomized study on the use of thalidomide administered either in a continually route or in cycles in association with high dose dexamethasone in patients with refractory or relapsed multiple myeloma.
OSPEDALE POLICLINICO S. MATTEO0 个研究点开始时间: 2005年9月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
3 期
Systemic treatment in severe cases of recurrent aphthous stomatitisRecurrent aphthous stomatitisACTRN12608000372381Hospital das Clínicas, Sao Paulo University40
Unknown
4 期
A Study of Thalidomide in the Treatment of Refractory Uremic PruritusHaemodialysisUremic PruritusThalidomideNCT05525234RenJi Hospital40
已完成
2 期
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate CancerProstatic NeoplasmNCT00001446National Cancer Institute (NCI)64
Unknown
不适用
The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing ChemotherapyChemotherapy-induced Nausea and VomitingNCT03601871Yunpeng Liu880
已完成
2 期
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple MyelomaMultiple MyelomaNCT00657488Celgene400